Skip to main content
SpringerLink
Log in

Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

Survival after pancreatic cancer surgery is extremely unfavorable even after curative resection. Prognostic factors have been explored but remain largely undefined. The present study was to identify the role of clinical and laboratory variables in the prognostic significance of resectable pancreatic adenocarcinoma. A total of 96 patients who underwent curative resection for pancreatic cancer were included. Survival was evaluated based on complete follow-up visits and was associated with potential prognostic factors using the Kaplan-Meier method and Cox proportional hazard model survival analyses. The results showed that prognostic variables significantly reduced survival, including old age, poorly differentiated tumors, elevated tumor markers and positive lymph node metastasis (LNM). Age of older than 60 years (HR=1.83, P=0.04), LNM (HR=2.22, P=0.01), lymph node ratio (0<LNR≤0.2, HR=1.38, P=0.042; LNR>0.2, HR=1.92, P=0.017), initial CA199 (HR=4.80, P=0.004), and CEA level (HR=2.59, P=0.019) were identified as independent prognostic factors by multivariate analysis. It was concluded that LNR may be potent predictor of survival and suggests that surgeons and the pathologists should thoroughly assess lymph nodes prior to surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014,64(1):9–29

    Article  PubMed  Google Scholar 

  2. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res, 2014,74(11):2913–2921

    Article  CAS  PubMed  Google Scholar 

  3. Sun H, Ma H, Hong G, et al. Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010. Sci Rep, 2014,4:6747

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Du L, DeFoe M, Ruzinova MB, et al. Perioperative therapy for surgically resectable pancreatic adenocarcinoma. Hematol Oncol Clin North Am, 2015,29(4):717–726

    Article  PubMed  PubMed Central  Google Scholar 

  5. Wray CJ, Ahmad SA, Matthews JB, et al. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology, 2005,128(6):1626–1641

    Article  PubMed  Google Scholar 

  6. Stojadinovic A, Brooks A, Hoos A, et al. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg, 2003,196(6):954–964

    Article  PubMed  Google Scholar 

  7. Yamamoto Y, Ikoma H, Morimura R, et al. The clinical impact of the lymph node ratio as a prognostic factor after resection of pancreatic cancer. Anticancer research, 2014,34(5):2389–2394

    PubMed  Google Scholar 

  8. Benassai G, Quarto G, Perrotta S, et al. Long-term survival after curative resection for pancreatic ductal adenocarcinoma-Surgical treatment. Int J Surg, 2015,21 Suppl 1:S1–3

    Article  PubMed  Google Scholar 

  9. Yamamoto T, Yagi S, Kinoshita H, et al. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis. World J Gastroenterol, 2015,21(1):262–268

    Article  PubMed  PubMed Central  Google Scholar 

  10. Li D, Chen C, Zhou Y, et al. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Medicine, 2015,94(35):e1345

    Article  Google Scholar 

  11. Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol, 2006,13(9):1189–1200

    Article  PubMed  Google Scholar 

  12. Fujii T. Extended lymphadenectomy in pancreatic cancer is crucial. World J Surg, 2013,37(8):1778–1781

    Article  PubMed  Google Scholar 

  13. Marmor S, Burke EE, Portschy PR, et al. Lymph node evaluation for treatment of adenocarcinoma of the pancreas. Surg Oncol, 2015,24(3):284–291

    Article  PubMed  Google Scholar 

  14. Dasari BV, Pasquali S, Vohra RS, et al. Extended versus standard lymphadenectomy for pancreatic head cancer: Meta-analysis of randomized controlled trials. J Gastrointest Surg, 2015,19(9):1725–1732

    Article  PubMed  Google Scholar 

  15. Jang JY, Kang MJ, Heo JS, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg, 2014,259(4):656–664

    Article  PubMed  Google Scholar 

  16. Pelucchi C, Galeone C, Polesel J, et al. Smoking and body mass index and survival in pancreatic cancer patients. Pancreas, 2014,43(1):47–52

    Article  PubMed  Google Scholar 

  17. Gaujoux S, Torres J, Olson S, et al. Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg Oncol, 2012,19(9):2908–2916.

    Article  PubMed  Google Scholar 

  18. Dandona M, Linehan D, Hawkins W, et al. Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer. Pancreas, 2011,40(6):931–937

    Article  PubMed  Google Scholar 

  19. Tramacere I, Scotti L, Jenab M, et al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer, 2010,126(6):1474–1486

    CAS  PubMed  Google Scholar 

  20. Olson SH, Chou JF, Ludwig E, et al. Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer, 2010,127(10):2412–2419

    Article  CAS  PubMed  Google Scholar 

  21. Park SM, Lim MK, Shin SA, et al. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol, 2006,24(31):5017–5024

    Article  PubMed  Google Scholar 

  22. Miura JT, Krepline AN, George B, et al. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery, 2015,158(6):1545–1555

    Article  PubMed  Google Scholar 

  23. Bolm L, Janssen S, Kasmann L, et al. Predicting survival after irradiation of metastases from pancreatic cancer. Anticancer Res, 2015,35(7):4105–4108

    PubMed  Google Scholar 

  24. Yang X, Hao J, Zhu CH, et al. Survival benefits of western and traditional Chinese Medicine treatment for patients with pancreatic cancer. Medicine, 2015,94(26):e1008

    Article  Google Scholar 

  25. Tanaka T, Ikeda M, Okusaka T, et al. Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol, 2008,38(11):755–761

    Article  PubMed  Google Scholar 

  26. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer, 2007,110(4):738–744

    Article  PubMed  Google Scholar 

  27. Fischer LK, Katz MH, Lee SM, et al. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology, 2016,68(2):210–220

    Article  PubMed  Google Scholar 

  28. Zhou D, Ye M, Bai Y, et al. Prognostic value of lymph node ratio in survival of patients with locally advanced rectal cancer. Can J Surg, 2015,58(4):237–244

    Article  PubMed  PubMed Central  Google Scholar 

  29. Zhao BW, Chen YM, Jiang SS, et al. Lymph node metastasis, a unique independent prognostic factor in early gastric cancer. PLoS One, 2015,10(7):e0129531

    Google Scholar 

  30. Yoo T, Lee WJ, Woo SM, et al. Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys, 2011,81(4):e623–630

    Article  Google Scholar 

  31. Chen Y, Gao SG, Chen JM, et al. Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients. Cell Biochem Biophys, 2015,71(3):1287–1291

    Article  CAS  PubMed  Google Scholar 

  32. O’Brien DP, Sandanayake NS, Jenkinson C, et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res, 2015,21(3):622–631

    Article  PubMed  Google Scholar 

  33. Tas F, Karabulut S, Ciftci R, et al. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Cancer Chemother Pharmacol, 2014,73(6):1163–1171

    Article  CAS  PubMed  Google Scholar 

  34. Lagergren J, Mattsson F, Zylstra J, et al. Extent of lymphadenectomy and prognosis after esophageal cancer surgery. JAMA Surg, 2016,151(1):32–39

    Article  PubMed  Google Scholar 

  35. Nimura Y, Nagino M, Takao S, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci, 2012,19(3):230–241

    Article  PubMed  Google Scholar 

  36. Chiang KC, Yeh CN, Ueng SH, et al. Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer. World J Surg Oncol, 2012,10:77

    Article  PubMed  PubMed Central  Google Scholar 

  37. Uson Junior PL, Franca MS, Rodrigues HV, et al. Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered. Einstein (Sao Paulo), 2015,13(3):347–351

    Article  Google Scholar 

  38. Yoon KW, Heo JS, Choi DW, et al. Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma. J Korean Surg Soc, 2011,81(6):394–401

    Article  PubMed  PubMed Central  Google Scholar 

  39. Lee SR, Kim HO, Son BH, et al. Prognostic factors associated with long-term survival and recurrence in pancreatic adenocarcinoma. Hepatogastroenterology, 2013,60(122):358–362

    CAS  PubMed  Google Scholar 

  40. Engelken FJ, Bettschart V, Rahman MQ, et al. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol, 2003,29(4):368–373

    Article  CAS  PubMed  Google Scholar 

  41. Krishnan S, Rana V, Janjan NA, et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 2006,107(11):2589–2596

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Professor Xiu NIE and Qin ZHANG in Department of Pathology, Union Hospital, Tongji Medical College for providing pathological data and valuable suggestions.

Author information

Author notes

  1. The authors contributed equally to this study.

Authors and Affiliations

  1. Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Rong Lin  (蔺 蓉), Chao-qun Han  (韩超群), Wei-jun Wang  (王玮珺), Jun Liu  (刘 俊), Wei Qian  (钱 伟), Zhen Ding  (丁 震) & Xiao-hua Hou  (侯晓华)

Authors
  1. Rong Lin  (蔺 蓉)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chao-qun Han  (韩超群)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei-jun Wang  (王玮珺)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Liu  (刘 俊)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei Qian  (钱 伟)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhen Ding  (丁 震)
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao-hua Hou  (侯晓华)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhen Ding  (丁 震).

Additional information

This study was supported in part by the National Natural Science Foundation of China (No. 81470039, No. 81330014, and No. 81272656).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, R., Han, Cq., Wang, Wj. et al. Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 37, 612–620 (2017). https://doi.org/10.1007/s11596-017-1780-2

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-017-1780-2

Key words

Search

Navigation